SCHEMBL31728941

SCHEMBL31728941

COc1cc(C#N)c(-c2ccc(F)c(Cl)c2F)c2ncnc(N)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EIF2AK3 Q9NZJ5 6/20 0.39
▸ MET P08581 1/20 0.36
▸ EGFR P00533 6/20 0.36
▸ SRC P12931 5/20 0.36
▸ ABL1 P00519 4/20 0.36
▸ HCK P08631 4/20 0.36
▸ KDR P35968 4/20 0.36
▸ PIK3CB P42338 4/20 0.36
▸ MTOR P42345 4/20 0.36
▸ PIK3CG P48736 4/20 0.36
▸ EPHB4 P54760 4/20 0.36
▸ PRKDC P78527 4/20 0.36
▸ PIK3CD O00329 3/20 0.36
▸ PIK3CA P42336 3/20 0.36
▸ MAP4K4 O95819 1/20 0.35
▸ LRRK2 Q5S007 2/20 0.35
▸ PDE5A O76074 1/20 0.34
▸ PI4KB Q9UBF8 2/20 0.34
▸ GSK3A P49840 1/20 0.34
▸ GSK3B P49841 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31729157 0.87 PDE5A (0.39) EIF2AK3EGFRSRCABL1HCK
SCHEMBL31727948 0.84 PIK3CD (0.35) METEGFRSRCABL1HCK
SCHEMBL31728714 0.84 FYN (0.39) EIF2AK3EGFRSRCABL1HCK
SCHEMBL31727929 0.80 KHK (0.37) EIF2AK3METEGFRSRCABL1
SCHEMBL31728491 0.80 MET (0.38) EIF2AK3METEGFRSRCABL1
SCHEMBL31728213 0.79 EIF2AK3 (0.38) EIF2AK3EGFRSRCABL1HCK
SCHEMBL31729150 0.79 ADK (0.43) EGFRSRCABL1KDRMAP4K4
SCHEMBL31728961 0.79 EGFR (0.38) EIF2AK3EGFRSRCABL1HCK
SCHEMBL31728591 0.77 EIF2AK3 (0.39) EIF2AK3EGFRSRCABL1HCK
SCHEMBL31727944 0.76 KHK (0.38) EIF2AK3METEGFRSRCABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235874-A1 HETEROCYCLICS AS EGFR INHIBITORS SCHRÖDINGER, INC. (US) 2025-11-13 — — WO disclosed
Send feedback